reweave: merge 24 files via frontmatter union [auto]

domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md

@@ -17,6 +17,7 @@ reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-06'}
 - International humanitarian law and AI alignment research independently converged on the same technical limitation that autonomous systems cannot be adequately predicted understood or explained|supports|2026-04-08
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
+- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10'}
 ---
 
 # Autonomous weapons systems capable of militarily effective targeting decisions cannot satisfy IHL requirements of distinction, proportionality, and precaution, making sufficiently capable autonomous weapons potentially illegal under existing international law without requiring new treaty text

domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md

@@ -15,6 +15,7 @@ related:
 reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|related|2026-04-08'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
+- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10'}
 supports:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck'}
 ---

domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md

@@ -18,6 +18,7 @@ reweave_edges:
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events|supports|2026-04-07
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-08"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 ---
 
 # FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality

domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md

@@ -18,6 +18,7 @@ reweave_edges:
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality|supports|2026-04-07
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-08"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 ---
 
 # FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events

domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md

@@ -18,10 +18,12 @@ reweave_edges:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver|supports|2026-04-07
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability|supports|2026-04-10
 supports:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
 ---
 
 # Hypertension-related cardiovascular mortality nearly doubled in the United States 2000–2023 despite the availability of effective affordable generic antihypertensives indicating that hypertension management failure is a behavioral and social determinants problem not a pharmacological availability problem

domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md

@@ -13,9 +13,11 @@ related_claims: ["[[Big Food companies engineer addictive products by hacking ev
 supports:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
 reweave_edges:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 - Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver|supports|2026-04-07
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability|supports|2026-04-10
 ---
 
 # Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden

domains/health/obbba-medicaid-work-requirements-destroy-enrollment-stability-required-for-vbc-prevention-roi.md

@@ -12,11 +12,13 @@ sourcer: AMA / Georgetown CCF / Urban Institute
 related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
 supports:
 - Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults
+- Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline
 challenges:
 - One Big Beautiful Bill Act (OBBBA)
 reweave_edges:
 - Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults|supports|2026-04-09
 - One Big Beautiful Bill Act (OBBBA)|challenges|2026-04-09
+- Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline|supports|2026-04-10
 ---
 
 # OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026

domains/health/obbba-snap-cuts-largest-food-assistance-reduction-history-186b-through-2034.md

@@ -10,8 +10,15 @@ agent: vida
 scope: structural
 sourcer: FRAC / Penn LDI / Urban Institute / Pew Charitable Trusts
 related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+supports:
+- SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years
+related:
+- OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden
+reweave_edges:
+- SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years|supports|2026-04-10
+- OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden|related|2026-04-10
 ---
 
 # OBBBA SNAP cuts represent the largest food assistance reduction in US history at $186 billion through 2034, removing continuous nutritional support from 2.4 million people despite evidence that SNAP participation reduces healthcare costs by 25 percent
 
-OBBBA's SNAP provisions cut $186 billion through 2034 through Thrifty Food Plan formula adjustments and work requirement expansions, making this the largest food assistance reduction in US history. The cuts are projected to remove 2.4 million people from SNAP by 2034, with more than 1 million older adults ages 55-64 at risk from work requirements alone, and 1 million+ facing short-term benefit loss in 2026. Implementation began December 1, 2025 in some states. The health implications are documented: SNAP participation is associated with 25% reduction in annual healthcare costs, and food insecurity is linked to higher risks of heart disease and diabetes. Among older adults specifically, food insecurity produces poorer diet quality, declining physical health, cognitive impairment risk, and harder chronic disease management. The OBBBA cuts are removing SNAP at the same time as Medicaid GLP-1 coverage is being cut, creating a double removal of continuous-support mechanisms. The Penn LDI projection of 93,000 deaths through 2039 from Medicaid cuts (3.2 million losing coverage) represents one mortality burden; the SNAP cuts are an additive burden affecting a partially overlapping population. The system is removing two parallel continuous-treatment interventions simultaneously, despite evidence that gains revert when support is removed.
+OBBBA's SNAP provisions cut $186 billion through 2034 through Thrifty Food Plan formula adjustments and work requirement expansions, making this the largest food assistance reduction in US history. The cuts are projected to remove 2.4 million people from SNAP by 2034, with more than 1 million older adults ages 55-64 at risk from work requirements alone, and 1 million+ facing short-term benefit loss in 2026. Implementation began December 1, 2025 in some states. The health implications are documented: SNAP participation is associated with 25% reduction in annual healthcare costs, and food insecurity is linked to higher risks of heart disease and diabetes. Among older adults specifically, food insecurity produces poorer diet quality, declining physical health, cognitive impairment risk, and harder chronic disease management. The OBBBA cuts are removing SNAP at the same time as Medicaid GLP-1 coverage is being cut, creating a double removal of continuous-support mechanisms. The Penn LDI projection of 93,000 deaths through 2039 from Medicaid cuts (3.2 million losing coverage) represents one mortality burden; the SNAP cuts are an additive burden affecting a partially overlapping population. The system is removing two parallel continuous-treatment interventions simultaneously, despite evidence that gains revert when support is removed.

domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md

@@ -13,10 +13,12 @@ attribution:
       context: "JACC longitudinal study 1999-2023, NHANES nationally representative data"
 supports:
 - hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability
 reweave_edges:
 - hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure|supports|2026-03-31
 - food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed|related|2026-04-03
 - generic digital health deployment reproduces existing disparities by disproportionately benefiting higher income users despite nominal technology access equity|related|2026-04-03
+- US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability|supports|2026-04-10
 related:
 - food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed
 - generic digital health deployment reproduces existing disparities by disproportionately benefiting higher income users despite nominal technology access equity
@@ -63,4 +65,4 @@ Relevant Notes:
 - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
 
 Topics:
-- [[_map]]
+- [[_map]]

domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md

@@ -10,8 +10,15 @@ agent: vida
 scope: correlational
 sourcer: Smolderen et al.
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
+related:
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+reweave_edges:
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|related|2026-04-10
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
 ---
 
 # Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 
-The SCORE study tracked 9,321 individuals with ASCVD and overweight/obesity (without diabetes) who initiated semaglutide 2.4mg, matched to 18,642 controls over mean 200-day follow-up. Semaglutide was associated with HR 0.43 for revised 3-point MACE and HR 0.55 for revised 5-point MACE (both p<0.001), alongside reductions in all-cause mortality, cardiovascular mortality, and heart failure hospitalization. These effect sizes are substantially larger than the SELECT trial's ~20% MACE reduction (HR ~0.80). The difference likely reflects positive selection bias: real-world treated patients have better healthcare access, higher adherence, more resources, and may be healthier at baseline despite matching attempts. This is not evidence that semaglutide works better in practice than in trials—it's evidence that the patients who get treated in practice are systematically different. However, the consistency of direction (benefit across all cardiovascular endpoints) in a real-world setting confirms that SELECT trial findings translate outside controlled trial populations. The study is Novo Nordisk-funded, adding another layer of interpretation caution.
+The SCORE study tracked 9,321 individuals with ASCVD and overweight/obesity (without diabetes) who initiated semaglutide 2.4mg, matched to 18,642 controls over mean 200-day follow-up. Semaglutide was associated with HR 0.43 for revised 3-point MACE and HR 0.55 for revised 5-point MACE (both p<0.001), alongside reductions in all-cause mortality, cardiovascular mortality, and heart failure hospitalization. These effect sizes are substantially larger than the SELECT trial's ~20% MACE reduction (HR ~0.80). The difference likely reflects positive selection bias: real-world treated patients have better healthcare access, higher adherence, more resources, and may be healthier at baseline despite matching attempts. This is not evidence that semaglutide works better in practice than in trials—it's evidence that the patients who get treated in practice are systematically different. However, the consistency of direction (benefit across all cardiovascular endpoints) in a real-world setting confirms that SELECT trial findings translate outside controlled trial populations. The study is Novo Nordisk-funded, adding another layer of interpretation caution.

domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md

@@ -25,6 +25,7 @@ reweave_edges:
 - All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-08"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 related:
 - All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 ---

domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md

@@ -15,6 +15,11 @@ related:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|supports|2026-04-10
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+supports:
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
 ---
 
 # Semaglutide's cardiovascular benefit is approximately 67-69% independent of weight or adiposity change, with anti-inflammatory pathways (hsCRP) accounting for more of the benefit than weight loss

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md

@@ -12,8 +12,10 @@ sourcer: STEER investigators / Nature Medicine
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
 supports:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|supports|2026-04-09
+- Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|supports|2026-04-10
 ---
 
 # Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md

@@ -14,6 +14,9 @@ related:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+supports:
+- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
 ---
 
 # Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction

domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md

@@ -14,10 +14,12 @@ supports:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
 - Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
 - US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
 reweave_edges:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
 - Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
 - US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10
 ---
 
 # US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health

domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md

@@ -12,8 +12,10 @@ sourcer: Yan et al. / JACC
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
 supports:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
 reweave_edges:
 - us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
+- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10
 ---
 
 # US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden

domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md

@@ -10,8 +10,10 @@ depends_on:
 - the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
 related:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain|related|2026-04-10
 ---
 
 # Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors

domains/space-development/China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years.md

@@ -5,7 +5,12 @@ description: "Tiangong station, lunar sample return, Long March 10 booster recov
 confidence: likely
 source: "Astra, web research compilation February 2026"
 created: 2026-03-20
-challenged_by: ["China's reusability timeline may be optimistic given that Long March 12A first-stage recovery failed in December 2025"]
+challenged_by:
+- China's reusability timeline may be optimistic given that Long March 12A first-stage recovery failed in December 2025
+related:
+- Chinese commercial launch vehicles have failed on debut at higher rates than Chinese state launch, creating a meaningful gap between China's strategic space ambitions and commercial launch capability
+reweave_edges:
+- Chinese commercial launch vehicles have failed on debut at higher rates than Chinese state launch, creating a meaningful gap between China's strategic space ambitions and commercial launch capability|related|2026-04-10
 ---
 
 # China is the only credible peer competitor in space with comprehensive capabilities and state-directed acceleration closing the reusability gap in 5-8 years
@@ -31,4 +36,4 @@ Relevant Notes:
 - [[reusable-launch-convergence-creates-us-china-duopoly-in-heavy-lift]] — the convergence toward two dominant launch providers
 
 Topics:
-- space exploration and development
+- space exploration and development

domains/space-development/anchor-customer-uncertainty-is-now-the-binding-constraint-for-commercial-station-programs.md

@@ -10,8 +10,12 @@ agent: astra
 scope: causal
 sourcer: SpaceNews
 related_claims: ["[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]", "[[commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030]]"]
+supports:
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain
+reweave_edges:
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain|supports|2026-04-10
 ---
 
 # Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
 
-NASA's January 28, 2026 freeze of CLD Phase 2 awards (planned for $1-1.5B across FY2026-2031) represents a phase transition in commercial station constraints. The freeze occurred exactly one week after the Trump administration inauguration, with no replacement timeline announced. This converted anticipated anchor customer revenue into uncertain future funding for multiple programs (Orbital Reef, potentially Starlab, Haven-2). The timing is significant: Axiom announced a $350M raise just two weeks later (February 12), suggesting they anticipated the freeze and moved to demonstrate capital independence, while other developers did not announce equivalent fundraises. The constraint has shifted from 'can we build it technically' and 'can we afford launch' to 'will the government customer materialize.' This is particularly striking because operational contracts (PAM missions to ISS) continued during the same period, indicating the freeze is specifically about large-scale development funding, not operational skepticism. The $4B funding shortfall that had already forced one program restructure (from fixed-price contracts to funded SAAs) suggests the governance uncertainty was building before the administration change made it explicit.
+NASA's January 28, 2026 freeze of CLD Phase 2 awards (planned for $1-1.5B across FY2026-2031) represents a phase transition in commercial station constraints. The freeze occurred exactly one week after the Trump administration inauguration, with no replacement timeline announced. This converted anticipated anchor customer revenue into uncertain future funding for multiple programs (Orbital Reef, potentially Starlab, Haven-2). The timing is significant: Axiom announced a $350M raise just two weeks later (February 12), suggesting they anticipated the freeze and moved to demonstrate capital independence, while other developers did not announce equivalent fundraises. The constraint has shifted from 'can we build it technically' and 'can we afford launch' to 'will the government customer materialize.' This is particularly striking because operational contracts (PAM missions to ISS) continued during the same period, indicating the freeze is specifically about large-scale development funding, not operational skepticism. The $4B funding shortfall that had already forced one program restructure (from fixed-price contracts to funded SAAs) suggests the governance uncertainty was building before the administration change made it explicit.

domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md

@@ -9,9 +9,15 @@ challenged_by:
 - Timeline slippage threatens a gap in continuous human orbital presence (unbroken since November 2000). Axiom's September 2024 cash crisis and down round shows how fragile commercial station timelines are. If none of the four achieve operational capability before ISS deorbits in 2031, the US could face its first period without permanent crewed LEO presence in 25 years.
 supports:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04
 - Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|related|2026-04-07
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors|supports|2026-04-10
+- Commercial station capital concentrates in the strongest contender rather than diversifying across the sector when government anchor customer commitments are uncertain|supports|2026-04-10
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline|supports|2026-04-10
 related:
 - Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
 ---

domains/space-development/governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers.md

@@ -5,7 +5,12 @@ description: "The shift from cost-plus proprietary programs to commercial-first
 confidence: likely
 source: "Astra synthesis from NASA COTS/CRS program history, Rocket Lab SDA contract, Space Force FY2026 budget, ISS commercial successor contracts"
 created: 2026-03-08
-challenged_by: "The transition is uneven — national security missions still require bespoke classified systems that commercial providers cannot serve off-the-shelf. Cost-plus contracting persists in programs where requirements are genuinely uncertain (e.g., SLS, deep-space habitats). The 'buyer not builder' framing may overstate how much has actually changed outside LEO launch services."
+challenged_by:
+- The transition is uneven — national security missions still require bespoke classified systems that commercial providers cannot serve off-the-shelf. Cost-plus contracting persists in programs where requirements are genuinely uncertain (e.g., SLS, deep-space habitats). The 'buyer not builder' framing may overstate how much has actually changed outside LEO launch services.
+related:
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market
+reweave_edges:
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market|related|2026-04-10
 ---
 
 # governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers
@@ -76,4 +81,4 @@ Relevant Notes:
 - [[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]] — SpaceX is the paradigm case of the commercial provider the new model advantages
 
 Topics:
-- [[_map]]
+- [[_map]]

domains/space-development/space-sector-commercialization-requires-independent-supply-and-demand-thresholds.md

@@ -10,8 +10,15 @@ agent: astra
 scope: structural
 sourcer: Astra
 related_claims: ["launch-cost-reduction-is-the-keystone-variable-that-unlocks-every-downstream-space-industry-at-specific-price-thresholds.md", "governments-are-transitioning-from-space-system-builders-to-space-service-buyers-which-structurally-advantages-nimble-commercial-providers.md"]
+supports:
+- The demand threshold in space is defined by revenue model independence from government anchor demand, not by revenue magnitude
+related:
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors
+reweave_edges:
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors|related|2026-04-10
+- The demand threshold in space is defined by revenue model independence from government anchor demand, not by revenue magnitude|supports|2026-04-10
 ---
 
 # Space sector commercialization requires two independent thresholds: a supply-side launch cost gate and a demand-side market formation gate
 
-The two-gate model explains why commercial space stations are stalling despite launch costs being at historic lows. Falcon 9 at $67M represents only 3% of Starlab's $2.8-3.3B development cost—the supply threshold was cleared years ago (~2018). Yet the NASA Phase 2 CLD freeze on January 28, 2026 immediately triggered capital crisis across multiple commercial station programs, demonstrating that government anchor demand remains load-bearing. This is structural evidence that the demand threshold has not been crossed. In contrast, satellite communications and Earth observation both activated WITHOUT ongoing government anchors after initial periods and now sustain themselves from private revenue. The model holds across all 7 sectors examined without counter-example: comms (both gates cleared, activated), EO (both gates cleared, activated), commercial stations (supply cleared, demand not cleared, stalled), in-space manufacturing (supply cleared, demand not cleared via AFRL dependence), lunar ISRU (supply approaching, demand not cleared), orbital debris removal (supply cleared, demand not cleared with no private payer). The ISS extension to 2032 congressional proposal is the clearest evidence: Congress is extending supply because commercial demand cannot sustain LEO human presence independently—it remains a strategic asset, not a commercial market.
+The two-gate model explains why commercial space stations are stalling despite launch costs being at historic lows. Falcon 9 at $67M represents only 3% of Starlab's $2.8-3.3B development cost—the supply threshold was cleared years ago (~2018). Yet the NASA Phase 2 CLD freeze on January 28, 2026 immediately triggered capital crisis across multiple commercial station programs, demonstrating that government anchor demand remains load-bearing. This is structural evidence that the demand threshold has not been crossed. In contrast, satellite communications and Earth observation both activated WITHOUT ongoing government anchors after initial periods and now sustain themselves from private revenue. The model holds across all 7 sectors examined without counter-example: comms (both gates cleared, activated), EO (both gates cleared, activated), commercial stations (supply cleared, demand not cleared, stalled), in-space manufacturing (supply cleared, demand not cleared via AFRL dependence), lunar ISRU (supply approaching, demand not cleared), orbital debris removal (supply cleared, demand not cleared with no private payer). The ISS extension to 2032 congressional proposal is the clearest evidence: Congress is extending supply because commercial demand cannot sustain LEO human presence independently—it remains a strategic asset, not a commercial market.

domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md

@@ -11,6 +11,13 @@ related:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors|supports|2026-04-10
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline|supports|2026-04-10
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market|supports|2026-04-10
+supports:
+- Commercial space station market has stratified into three tiers by development phase with manufacturing-ready programs holding structural advantage over design-phase competitors
+- No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline
+- Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market
 ---
 
 # The commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit

entities/space-development/aetherflux.md

@@ -9,6 +9,10 @@ status: active
 industry: [space-based solar power, orbital data centers, space infrastructure]
 website: 
 domain: space-development
+supports:
+- Breakthrough Energy Ventures' investment in Aetherflux's orbital solar infrastructure signals that space-based solar power has achieved credibility as a climate technology investment category at institutional investor level
+reweave_edges:
+- Breakthrough Energy Ventures' investment in Aetherflux's orbital solar infrastructure signals that space-based solar power has achieved credibility as a climate technology investment category at institutional investor level|supports|2026-04-10
 ---
 
 # Aetherflux